Oxford BioTherapeutics and Roche link on antibody cancer treatments
Pharmaceutical Technology
MARCH 20, 2025
OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.
Antibody Related Topics 
J&J antibody drug combination shows promise in multiple myeloma
Bio Pharma Dive
MAY 25, 2023
A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.
Antibody 
357
357 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.
Antibody 347
347 
Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug
Bio Pharma Dive
NOVEMBER 9, 2020
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact.
Antibody 337
337 
AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody
Pharmaceutical Technology
MAY 23, 2024
AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.
Antibody 288
288 Antibody 288
288 
Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround.
Antibody 336
336 
Who would get Regeneron's COVID-19 antibody treatment?
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
Antibody 307
307 
A startup raises $336M to make a better antibody drug for COVID-19
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.
Antibody 336
336 
J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies
Bio Pharma Dive
MAY 24, 2021
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.
Antibody 318
318 
Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.
Genetics 307
307 
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.
Antibody 304
304 
Twist Bioscience and Astellas team up for antibody discovery
Pharmaceutical Technology
APRIL 21, 2023
Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.
Antibody 264
264 
In multiple myeloma, cell therapies lead but antibody drugs could follow fast
Bio Pharma Dive
DECEMBER 8, 2020
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind. Two cell therapies might soon be approved for the blood cancer.
Antibody 301
301 
Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use.
Antibody 306
306 
Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs
Bio Pharma Dive
JULY 28, 2021
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.
Antibody 301
301 
Talem and Libera Bio partner for discovery of AI-driven antibodies
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.
Antibody 262
262 
AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.
Antibody 264
264 
Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.
Antibody 261
261 
Japan grants patent for BioArctic’s Parkinson’s disease antibody
Pharmaceutical Technology
AUGUST 24, 2023
Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.
Antibody 245
245 
Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Licensing 241
241 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
US buys up supply of new Lilly antibody meant to work versus omicron
Bio Pharma Dive
FEBRUARY 11, 2022
Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday.
Antibody 273
273 Antibody 273
273 
US FDA approves Eisai-Biogen’s antibody for Alzheimer’s
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
FDA Approval 246
246 
AbbVie announces acquisition of DJS Antibodies for $255m
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Antibody 217
217 
US pauses distribution of Regeneron, Lilly antibodies over omicron concerns
Bio Pharma Dive
DECEMBER 23, 2021
The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.
Antibody 347
347 
Versant partners with AbCellera to arm startups with better antibodies
Bio Pharma Dive
JULY 27, 2022
The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO.
Antibody 334
334 Antibody 334
334 
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
Bio Pharma Dive
MAY 25, 2023
Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.
Antibody 321
321 
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
Bio Pharma Dive
APRIL 21, 2023
A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.
Antibody 196
196 
Zenas, with new funding, aims dual-targeting antibody at lupus and MS
Bio Pharma Dive
MAY 7, 2024
The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.
Antibody 184
184 
FDA Animal Testing Phase-Out Targets Monoclonal Antibodies
XTalks
APRIL 14, 2025
The roadmap initially targets monoclonal antibodies (mAbs) and similar biologic therapies drugs engineered to bind precise disease targets before expanding to other drug classes. On April 10, 2025, the FDA unveiled a new plan to phase out its animal testing requirements, refocusing the FDAs animal testing policy towards other methods.
Antibody 59
59 
BioNTech and OncoC4 sign deal to co-develop antibody for solid tumours
Pharmaceutical Technology
MARCH 20, 2023
BioNTech has signed an exclusive worldwide licence and collaboration agreement with OncoC4 to co-develop and commercialise a new checkpoint antibody in multiple solid tumour indications. BioNTech will solely develop all the combinations other than the PD-1 inhibition.
Antibody 246
246 
A chain reaction: HIV vaccines can lead to antibodies against antibodies
Medical Xpress
JANUARY 17, 2025
Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. Many vaccines work by introducing a protein to the body that resembles part of a virus.
Antibody 144
144 
Lilly to test COVID-19 antibody drug in unorthodox nursing home study
Bio Pharma Dive
AUGUST 3, 2020
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.
Nurses 341
341 
Lilly asks FDA to revoke clearance of first COVID-19 antibody drug
Bio Pharma Dive
APRIL 16, 2021
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug.
Antibody 339
339 
AbbVie and Xilio to collaborate on antibody-based immunotherapies
Pharmaceutical Technology
FEBRUARY 13, 2025
AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based immunotherapies.
Antibody 162
162 
Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 7, 2020
The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination.
Antibody 337
337 
Merck antibody reduces RSV-related disease, hospitalizations in trial
Bio Pharma Dive
OCTOBER 18, 2024
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
Antibody 274
274 
Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline
Pharmaceutical Technology
APRIL 8, 2025
Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies alternative antibody isotopes for cancer.
Antibody 130
130 
Merck bets $700M on an antibody drug’s potential in immune diseases
Bio Pharma Dive
AUGUST 9, 2024
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
Antibody 293
293 
GSK antibody drug reduces COPD attacks in trial
Bio Pharma Dive
SEPTEMBER 6, 2024
New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.
Trials 259
259 
Bispecific antibody startup Bambusa raises $90m to fund clinical trials
Pharmaceutical Technology
FEBRUARY 17, 2025
Two of Bambusas bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in 2025.
Antibody 162
162 
Can new Regeneron, Lilly data move the needle for COVID-19 antibody drugs?
Bio Pharma Dive
JANUARY 26, 2021
The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high.
Antibody 337
337 
IPA and Ribopro form mRNA antibody discovery collaboration
Pharmaceutical Technology
FEBRUARY 27, 2025
IPA has entered a strategic partnership with Ribopro aiming to transform therapeutic antibody discovery and development.
Antibody 147
147 
Lilly offers first evidence that its antibody drug may help treat COVID-19
Bio Pharma Dive
SEPTEMBER 16, 2020
The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear.
Antibody 326
326 
Let's personalize your content